AVADEL PHARMACEUTICALS PLC's ticker is AVDL and the CUSIP is 05337M104. A total of 82 filers reported holding AVADEL PHARMACEUTICALS PLC in Q3 2020. The put-call ratio across all filers is 0.74 and the average weighting 0.1%.
Quarter-by-quarter ownership
Value | Shares | Weighting | ||||
---|---|---|---|---|---|---|
Q1 2021 | $188,000 | +34.3% | 20,781 | -1.1% | 0.00% | – |
Q4 2020 | $140,000 | +28.4% | 21,019 | -2.7% | 0.00% | – |
Q3 2020 | $109,000 | -37.7% | 21,600 | -0.3% | 0.00% | – |
Q2 2020 | $175,000 | +48.3% | 21,663 | +45.2% | 0.00% | – |
Q1 2020 | $118,000 | 0.0% | 14,919 | -4.4% | 0.00% | – |
Q4 2019 | $118,000 | +81.5% | 15,610 | -0.3% | 0.00% | – |
Q3 2019 | $65,000 | +44.4% | 15,660 | +0.1% | 0.00% | – |
Q2 2019 | $45,000 | +87.5% | 15,646 | -7.0% | 0.00% | – |
Q1 2019 | $24,000 | -45.5% | 16,824 | -2.1% | 0.00% | – |
Q4 2018 | $44,000 | -42.9% | 17,184 | -2.0% | 0.00% | – |
Q3 2018 | $77,000 | -18.9% | 17,536 | +13.3% | 0.00% | – |
Q2 2018 | $95,000 | -5.9% | 15,473 | +11.5% | 0.00% | – |
Q1 2018 | $101,000 | -12.9% | 13,871 | -2.1% | 0.00% | – |
Q4 2017 | $116,000 | -24.7% | 14,172 | -3.6% | 0.00% | – |
Q3 2017 | $154,000 | -7.2% | 14,706 | -2.3% | 0.00% | – |
Q2 2017 | $166,000 | +7.1% | 15,048 | -6.0% | 0.00% | – |
Q1 2017 | $155,000 | – | 16,009 | – | 0.00% | – |
Download |
Other shareholders
Name | Shares | Value | Weighting ↓ |
---|---|---|---|
Stonepine Capital Management, LLC | 985,210 | $10,345,000 | 6.10% |
Broadfin Capital, LLC | 3,568,122 | $37,465,000 | 5.54% |
JW Asset Management, LLC | 444,439 | $4,667,000 | 3.42% |
ARMISTICE CAPITAL, LLC | 1,688,000 | $17,724,000 | 2.09% |
DEERFIELD MANAGEMENT COMPANY, L.P. (SERIES C) | 3,655,494 | $38,383,000 | 1.73% |
FALCON POINT CAPITAL, LLC | 661,490 | $6,284,000 | 0.91% |
KNOTT DAVID M | 158,555 | $1,665,000 | 0.71% |
Perceptive Advisors | 3,098,010 | $32,530,000 | 0.62% |
Sio Capital Management, LLC | 91,413 | $960,000 | 0.50% |
HEARTLAND ADVISORS INC | 700,000 | $7,350,000 | 0.48% |